[go: up one dir, main page]

WO2018170709A1 - Vecteur d'expression du gène tnlg5a humain et son application - Google Patents

Vecteur d'expression du gène tnlg5a humain et son application Download PDF

Info

Publication number
WO2018170709A1
WO2018170709A1 PCT/CN2017/077396 CN2017077396W WO2018170709A1 WO 2018170709 A1 WO2018170709 A1 WO 2018170709A1 CN 2017077396 W CN2017077396 W CN 2017077396W WO 2018170709 A1 WO2018170709 A1 WO 2018170709A1
Authority
WO
WIPO (PCT)
Prior art keywords
tnlg5a
pegfp
gene
vector
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2017/077396
Other languages
English (en)
Chinese (zh)
Inventor
毛吉炎
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shenzhen Biocan Technologies Co Ltd
Original Assignee
Shenzhen Biocan Technologies Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen Biocan Technologies Co Ltd filed Critical Shenzhen Biocan Technologies Co Ltd
Priority to PCT/CN2017/077396 priority Critical patent/WO2018170709A1/fr
Publication of WO2018170709A1 publication Critical patent/WO2018170709A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Definitions

  • the present invention belongs to the field of biotechnology, and relates to a method for constructing a human TNLG5A gene expression vector and an application thereof.
  • ILA belongs to the TNFR superfamily and is mainly expressed in activated T cells and is an inducible T cell surface receptor;
  • TNLG5A belongs to the TNF superfamily and is mainly expressed in concentrated antigen presenting cells (APC).
  • APC concentrated antigen presenting cells
  • IL A/TNLG5A is another important costimulatory molecule other than CD28/B7, which may or may not be dependent on CD28/
  • the B7 pathway mediates the production of costimulatory signals that induce T cell activation, proliferation, and cytokine secretion.
  • ILA and its ligand system have two-way signal transduction, which can transmit cells to T cells through TNLG5A, and can transmit signals to cells expressing ligands, which plays an important role in tumor immunotherapy, and needs to be done.
  • a large number of studies can achieve clinical transformation, but the lack of recombinant vectors with high expression of TNLG5A gene in the prior art has hindered the progress of related research.
  • the object of the present invention is to overcome the deficiencies in the prior art and to provide a method for constructing a human TNLG5A gene expression vector.
  • the expression vector pEGFP-Cl/TNLG5A was constructed, which laid a foundation for the subsequent study of human TNLG5A gene function.
  • a method for constructing a human TNLG5A gene overexpression vector comprising the steps of:
  • RNA of Jurkat cells was extracted and reverse transcribed into cDNA, and primers TNLG5A-F and TNLG5A-R were designed.
  • the cDNA was used as a template, and primers and PrimeStar high-fidelity DNA polymerase were used for PCR amplification according to a conventional method.
  • the reaction conditions were : 98 ° C 2 min; 98 ° C 10 s, 58 ° C 10 s, 72 ° C 50 s, 30 cycles; 72 ° C 5 min.
  • the PCR amplification products were identified by agarose gel electrophoresis.
  • the purified PCR product and the eukaryotic expression vector pEGFP-Cl were digested with restriction enzymes Xho I and EcoR I, identified and recovered by 1% agarose gel electrophoresis;
  • the target gene fragment was ligated with the same double-digested expression vector pEGFP-Cl; the reaction system was: 10XT4 DNA ligase Buffer 1 ⁇ , linearized pEGFP-Cl vector 1 ⁇ , PCR product 3 ⁇ , T4 DNA ligase 1 ⁇ , dH20 4 L, 4 °C ligation overnight; the ligation product was transformed into E.
  • coli DH5ot competent cells ice bath for 30 min, heat shock at 42 °C for 90 s, immediately transferred to ice for 2 min, then added to 500 37
  • the pre-warmed non-resistant LB medium was incubated at 37 °C for 1 h.
  • the bacterial solution was uniformly coated on LB solid medium containing kanamycin, and placed in a 37 ° C incubator for overnight culture. Positive colonies were screened; 3 monoclonal colonies were randomly picked. After the colony PCR was positive, the bacterial liquid was sent to Shanghai Biotech for sequencing.
  • the obtained recombinant eukaryotic expression plasmid was named pEGFP-Cl/TNLG5A.
  • the present invention constructs the overexpression vector pEGFP-Cl/TNLG5A of the TNLG5A gene. Subsequent development of the TNLG5A gene will play an important role in TNLG5A-related drug research and development.
  • 1 is the relative level of the TNLG5 A gene of 293T cells transfected with pEGFP-C 1/TNLG5 A vector.
  • Jurkat cells and 293T cells were purchased from ATCC, Premix PrimeSTAR
  • HS enzyme was purchased from Takara, RNeasy Mini Kit was purchased from QIAGEN, Endo-Free Plasmid
  • Mini Kit II was purchased from Omega bio-tek.
  • the purified PCR product and the eukaryotic expression vector pEGFP-Cl were digested with restriction enzymes Xho I and EcoR I, identified and recovered by 1% agarose gel electrophoresis;
  • the target gene fragment was ligated with the same double-digested expression vector pEGFP-Cl; the reaction system was: 10XT4 DNA ligase Buffer 1 ⁇ , linearized pEGFP-Cl vector 1 ⁇ , PCR product 3 ⁇ , T4 DNA ligase 1 ⁇ , dH20 4 L, 4 °C ligation overnight; the ligation product was transformed into E.
  • coli DH5ot competent cells ice bath for 30 min, heat shock at 42 °C for 90 s, immediately transferred to ice for 2 min, then added to 500 37
  • the pre-warmed non-resistant LB medium was incubated at 37 °C for 1 h.
  • the bacterial solution was uniformly coated on LB solid medium containing kanamycin, and placed in a 37 ° C incubator for overnight culture. Positive colonies were screened; 3 monoclonal colonies were randomly picked. After the colony PCR was positive, the bacterial liquid was sent to Shanghai Biotech for sequencing.
  • the obtained recombinant eukaryotic expression plasmid was named pEGFP-Cl/TNLG5A.
  • the primer design software Oligo 7.0 was used to design bows [0023] , CR production of the country
  • GGGTCGG GA@CTTTGeCCeG
  • Kit extracts total RNA from each group of cells, using PrimeScrip RT reagent
  • Kit reverse transcribes mRNA into cDNA and stores at -20 °C.
  • TNLG5A As a template, GAPDH was used as an internal reference, and the relative expression of TNLG5A was detected by real-time PCR. The reaction conditions were set: 95 ° C for 30 s, 1 cycle, 95 ° C for 10 s, and 54 ° C for 30 s for 40 cycles. The relative expression of TNLG5A gene in each group was detected by SYBR Primescript RT-PCR Kit. The results are shown in Figure 1. It can be seen that the expression level of TNLG5A gene in 293T cells transfected with pEGFP-Cl/TNLG5A plasmid is 170-fold higher than that of normal 293T cells, indicating that the pEGFP-Cl/TNLG5A plasmid can be specific, sustained and efficient. , stably promote high expression of TNLG5A gene.
  • the present invention constructs the overexpression vector pEGFP-Cl/TNLG5A of the TNLG5A gene. Subsequent development of the TNLG5A gene will play an important role in TNLG5A-related drug research and development.

Landscapes

  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne une méthode de construction d'un vecteur d'expression du gène TNLG5A humain, comprenant les étapes suivantes : (1) clonage d'un gène TNLG5A ; et (2) construction d'un vecteur de surexpression pEGFP-Cl/TNLG5A.
PCT/CN2017/077396 2017-03-20 2017-03-20 Vecteur d'expression du gène tnlg5a humain et son application Ceased WO2018170709A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/CN2017/077396 WO2018170709A1 (fr) 2017-03-20 2017-03-20 Vecteur d'expression du gène tnlg5a humain et son application

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2017/077396 WO2018170709A1 (fr) 2017-03-20 2017-03-20 Vecteur d'expression du gène tnlg5a humain et son application

Publications (1)

Publication Number Publication Date
WO2018170709A1 true WO2018170709A1 (fr) 2018-09-27

Family

ID=63584510

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2017/077396 Ceased WO2018170709A1 (fr) 2017-03-20 2017-03-20 Vecteur d'expression du gène tnlg5a humain et son application

Country Status (1)

Country Link
WO (1) WO2018170709A1 (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101528779A (zh) * 2006-10-16 2009-09-09 斯克利普斯研究院 炎症性疾病中的4-1bb配体

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101528779A (zh) * 2006-10-16 2009-09-09 斯克利普斯研究院 炎症性疾病中的4-1bb配体

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE Nucleotide 1 September 2016 (2016-09-01), GOODWIN RG: "Homo sapiens tumor necrosis factor superfamily member 9 (TNFSF9), mRNA", XP055608407, retrieved from NCBI Database accession no. NM_003811 *
SUN, SHUNTAO ET AL.,: "Construction of Expression Vector with Human Costimulatory Molecules 4-1BBL and its Stable Expression in Tca8113 Cells", CHINA JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY, vol. 6, no. 3, 31 May 2008 (2008-05-31), pages 188 - 193 *

Similar Documents

Publication Publication Date Title
RU2014128987A (ru) Быстрый способ клонирования и экспрессии сегментов гена родственной вариабельной области антитела
CN106947766B (zh) 一种枯草芽孢杆菌具有启动子功能的dna片段及其应用
CN105985978A (zh) 一种新型rna环化表达载体的构建及其应用
CN109266650B (zh) 一种诱导型启动子、其重组载体、转化体以及诱导基因表达的方法及其应用
CN103981112A (zh) 一种高产菊粉内切酶的双启动子多拷贝重组毕赤酵母菌株
CN116926068A (zh) 转录中介体med31基因及其互作转录因子在提高三角褐指藻中岩藻黄素含量的应用
CN106086025B (zh) 一种具有启动子功能的dna片段及其应用
CN108823222A (zh) 白背飞虱几丁质合成酶1（SfCHS1）基因片段及其dsRNA在害虫防治中的应用
WO2018170709A1 (fr) Vecteur d'expression du gène tnlg5a humain et son application
WO2018170708A1 (fr) Méthode de construction d'un vecteur d'expression du gène ila humain et son application
WO2018170711A1 (fr) Vecteur d'expression élevée du gène gp34 humain et son application
WO2018170710A1 (fr) Vecteur d'expression élevée du gène imd16 humain et son application
CN104830744A (zh) 利用sd-as序列偶联(r)-羰基还原酶与葡萄糖脱氢酶制备(r)-苯乙二醇的方法
CN115838713A (zh) 一种蛋白酶及其在l-肌肽合成中的应用
CN115896211A (zh) 一种发酵生产胞磷胆碱的基因工程菌及应用
CN108486098B (zh) 一种用SLFN13从总RNA中纯化总mRNA的方法
WO2019237391A1 (fr) Inactivation ciblée par crispr/cas9 du gène txgp1 humain et arng spécifique associé
WO2019000145A1 (fr) Procédé de construction de cellule cho recombinée exprimant fortement l'ampar
CN107119051B (zh) 一种巨大芽孢杆菌具有启动子功能的dna片段及其应用
CN117568301B (zh) 一种通过糖多孢红霉菌sace_1646基因提高红霉素产量的方法
CN111826357A (zh) 三分三非典型iii型聚酮合酶及其应用
CN111378654B (zh) 用于细胞内重组蛋白固定的三角形网状rna支架及其构建方法与应用
WO2017214940A1 (fr) Vecteur d'expression lentiviral pour favoriser spécifiquement l'expression élevée du gène cplx2, et ses applications
CN108753750A (zh) 白背飞虱几丁质合成酶1a(SfCHS1a)基因可变性剪切子及其dsRNA在害虫防治中的应用
WO2019000152A1 (fr) Cellule cho exprimant le gène rhbdd1 et son utilisation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17902487

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17902487

Country of ref document: EP

Kind code of ref document: A1